199 related articles for article (PubMed ID: 16413244)
1. Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients.
Masuda S; Goto M; Fukatsu S; Uesugi M; Ogura Y; Oike F; Kiuchi T; Takada Y; Tanaka K; Inui K
Clin Pharmacol Ther; 2006 Jan; 79(1):90-102. PubMed ID: 16413244
[TBL] [Abstract][Full Text] [Related]
2. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K
Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
[TBL] [Abstract][Full Text] [Related]
3. Relation between mRNA expression level of multidrug resistance 1/ABCB1 in blood cells and required level of tacrolimus in pediatric living-donor liver transplantation.
Goto M; Masuda S; Kiuchi T; Ogura Y; Oike F; Tanaka K; Uemoto S; Inui K
J Pharmacol Exp Ther; 2008 May; 325(2):610-6. PubMed ID: 18252812
[TBL] [Abstract][Full Text] [Related]
4. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
Zhang X; Liu ZH; Zheng JM; Chen ZH; Tang Z; Chen JS; Li LS
Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
[TBL] [Abstract][Full Text] [Related]
5. Impact of cytochrome P450 3A5 polymorphism in graft livers on the frequency of acute cellular rejection in living-donor liver transplantation.
Uesugi M; Kikuchi M; Shinke H; Omura T; Yonezawa A; Matsubara K; Fujimoto Y; Okamoto S; Kaido T; Uemoto S; Masuda S
Pharmacogenet Genomics; 2014 Jul; 24(7):356-66. PubMed ID: 24911663
[TBL] [Abstract][Full Text] [Related]
6. Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients.
Barrera-Pulido L; Aguilera-García I; Docobo-Pérez F; Alamo-Martínez JM; Pareja-Ciuró F; Nuñez-Roldán A; Gómez-Bravo MA; Bernardos-Rodríguez A
Transplant Proc; 2008 Nov; 40(9):2949-51. PubMed ID: 19010156
[TBL] [Abstract][Full Text] [Related]
7. Influence of cytochrome P450 (CYP) 3A4*1G polymorphism on the pharmacokinetics of tacrolimus, probability of acute cellular rejection, and mRNA expression level of CYP3A5 rather than CYP3A4 in living-donor liver transplant patients.
Uesugi M; Hosokawa M; Shinke H; Hashimoto E; Takahashi T; Kawai T; Matsubara K; Ogawa K; Fujimoto Y; Okamoto S; Kaido T; Uemoto S; Masuda S
Biol Pharm Bull; 2013; 36(11):1814-21. PubMed ID: 24189425
[TBL] [Abstract][Full Text] [Related]
8. Haplotypic structure of ABCB1/MDR1 gene modifies the risk of the acute allograft rejection in renal transplant recipients.
Bandur S; Petrasek J; Hribova P; Novotna E; Brabcova I; Viklicky O
Transplantation; 2008 Nov; 86(9):1206-13. PubMed ID: 19005401
[TBL] [Abstract][Full Text] [Related]
9. Forkhead box P3 (FOXP3) mRNA expression immediately after living-donor liver transplant.
Sakamoto R; Asonuma K; Zeledon Ramirez ME; Yoshimoto K; Nishimori A; Inomata Y
Exp Clin Transplant; 2009 Mar; 7(1):8-12. PubMed ID: 19364305
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of tacrolimus in living donor liver transplant and deceased donor liver transplant recipients.
Jain A; Venkataramanan R; Sharma R; Kwong T; Orloff M; Abt P; Kashyap R; Tsoulfas G; Batzold P; Williamson M; Bozorgzadeh A
Transplantation; 2008 Feb; 85(4):554-60. PubMed ID: 18347534
[TBL] [Abstract][Full Text] [Related]
11. Comparison of cyclosporine microemulsion and tacrolimus in 39 recipients of living donor liver transplantation.
Tanaka K; Lake J; Villamil F; Levy G; Marotta P; Mies S; de Hemptinne B; Moench C
Liver Transpl; 2005 Nov; 11(11):1395-402. PubMed ID: 16237691
[TBL] [Abstract][Full Text] [Related]
12. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
Quteineh L; Verstuyft C; Furlan V; Durrbach A; Letierce A; Ferlicot S; Taburet AM; Charpentier B; Becquemont L
Basic Clin Pharmacol Toxicol; 2008 Dec; 103(6):546-52. PubMed ID: 19067682
[TBL] [Abstract][Full Text] [Related]
13. Repeating intraportal donor-specific transfusion may induce tolerance following adult living-related donor liver transplantation.
Sato Y; Ichida T; Watanabe H; Yamamoto S; Oya H; Nakatsuka H; Kobayashi T; Watanabe T; Kameyama H; Hatakeyama K
Hepatogastroenterology; 2003; 50(51):601-6. PubMed ID: 12828042
[TBL] [Abstract][Full Text] [Related]
14. Higher initial tacrolimus blood levels and concentration-dose ratios in kidney transplant recipients who develop diabetes mellitus.
Rodrigo E; de Cos MA; Fernández-Fresnedo G; Sánchez B; Ruiz JC; Piñera C; Palomar R; Cotorruelo JG; Gómez-Alamillo C; de Castro SS; de Francisco AL; Arias M
Transplant Proc; 2005 Nov; 37(9):3819-20. PubMed ID: 16386549
[TBL] [Abstract][Full Text] [Related]
15. A nomogram for predicting the optimal oral dosage of tacrolimus in liver transplant recipients with small-for-size grafts.
Kishino S; Ohno K; Shimamura T; Furukawa H; Todo S
Clin Transplant; 2006; 20(4):443-9. PubMed ID: 16842519
[TBL] [Abstract][Full Text] [Related]
16. Initial dosage adjustment for oral administration of tacrolimus using the intestinal MDR1 level in living-donor liver transplant recipients.
Masuda S; Goto M; Okuda M; Ogura Y; Oike F; Kiuchi T; Tanaka K; Inui K
Transplant Proc; 2005 May; 37(4):1728-9. PubMed ID: 15919446
[TBL] [Abstract][Full Text] [Related]
17. The MDR1/ABCB1 gene, a high-impact risk factor for cardiac transplant rejection.
Barnard JB; Richardson S; Sheldon S; Fildes J; Pravica V; Hutchinson IV; Leonard CT; Yonan N
Transplantation; 2006 Dec; 82(12):1677-82. PubMed ID: 17198259
[TBL] [Abstract][Full Text] [Related]
18. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation.
Goto M; Masuda S; Kiuchi T; Ogura Y; Oike F; Okuda M; Tanaka K; Inui K
Pharmacogenetics; 2004 Jul; 14(7):471-8. PubMed ID: 15226679
[TBL] [Abstract][Full Text] [Related]
19. Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism.
Zheng H; Zeevi A; Schuetz E; Lamba J; McCurry K; Griffith BP; Webber S; Ristich J; Dauber J; Iacono A; Grgurich W; Zaldonis D; McDade K; Zhang J; Burckart GJ
J Clin Pharmacol; 2004 Feb; 44(2):135-40. PubMed ID: 14747421
[TBL] [Abstract][Full Text] [Related]
20. The impact of pharmacogenomic factors on acute persistent rejection in adult lung transplant patients.
Zheng HX; Zeevi A; McCurry K; Schuetz E; Webber S; Ristich J; Zhang J; Iacono A; Dauber J; McDade K; Zaldonis D; Lamba J; Burckart GJ
Transpl Immunol; 2005 Mar; 14(1):37-42. PubMed ID: 15814280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
